PMID- 27145825
OWN - NLM
STAT- MEDLINE
DCOM- 20171010
LR  - 20191027
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
VI  - 14
IP  - 5
DP  - 2016
TI  - Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic 
      Chronic Heart Failure.
PG  - 481-486
AB  - OBJECTIVE: Chronic heart failure (CHF) remains a major health problem, with high 
      levels of morbidity and mortality and a low health-related quality of life 
      (HRQoL). We assessed the impact on HRQoL of adding the If channel blocker, 
      ivabradine, to a standard treatment regimen of patients with ischaemic CHF 
      (I-CHF) and heart rate (HR) >/=70 beats/min (bpm). METHODS: A randomized 
      prospective study of 100 consecutive patients presenting with stable I-CHF, left 
      ventricular ejection fraction (LVEF) <40% and a sinus HR >/=70 bpm. New York Heart 
      Association (NYHA) class, overall summary score (OSS) and clinical summary score 
      (CSS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ) were used to assess 
      HRQoL. The patients were randomized into 2 groups: carvedilol only (group I 
      (n=50)) and carvedilol + ivabradine (group II (n=50)). The patients were followed 
      up for 12 weeks and their HRQoL scores were monitored and compared. RESULTS: The 
      overall mean age of the cohort was 63+/-10 years with 70% (n=70) males. HRQoL 
      scores had significantly improved in group II after 12 weeks of follow-up. The 
      net proportion of patients with a 5-point improvement in CSS was 30% higher in 
      group II (p=0.002), whereas that for the OSS, it was 24% (p=0.001), when compared 
      with group I. These improvements were accompanied by a significant HR reduction 
      (69 vs 78 bpm; p=0.002). CONCLUSION: Adding ivabradine to the standard drug 
      regimen, currently advocated by guidelines for CHF with a heart rate >/=70 bpm, 
      resulted in a significant improvement in HRQoL.
FAU - Sallam, Mansour
AU  - Sallam M
AD  - Sr. Consultant Cardiologist, Sultan Qaboos University Hospital, Oman, Ass. Prof. 
      of Cardiology, Al-Azhar University, Cairo, Egypt, P.O. Box 35; Postal Code: 123, 
      Al-Khod, Muscat, Sultanate of Oman. mansoursallam@yahoo.com.
FAU - Al-Saadi, Tariq
AU  - Al-Saadi T
FAU - Alshekaili, Latifa
AU  - Alshekaili L
FAU - Al-Zakwani, Ibrahim
AU  - Al-Zakwani I
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Adrenergic Antagonists)
RN  - 0 (Benzazepines)
RN  - 0 (Carbazoles)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Propanolamines)
RN  - 0K47UL67F2 (Carvedilol)
RN  - 3H48L0LPZQ (Ivabradine)
SB  - IM
MH  - Adrenergic Antagonists/therapeutic use
MH  - Aged
MH  - Benzazepines/adverse effects/*therapeutic use
MH  - Carbazoles/therapeutic use
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - Carvedilol
MH  - Chronic Disease
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heart Failure/diagnosis/*drug therapy/physiopathology/psychology
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Ivabradine
MH  - Male
MH  - Middle Aged
MH  - Oman
MH  - Propanolamines/therapeutic use
MH  - Prospective Studies
MH  - *Quality of Life
MH  - Stroke Volume/drug effects
MH  - Surveys and Questionnaires
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ventricular Function, Left/drug effects
EDAT- 2016/05/06 06:00
MHDA- 2017/10/11 06:00
CRDT- 2016/05/06 06:00
PHST- 2016/03/01 00:00 [received]
PHST- 2016/04/26 00:00 [revised]
PHST- 2016/04/26 00:00 [accepted]
PHST- 2016/05/06 06:00 [pubmed]
PHST- 2017/10/11 06:00 [medline]
PHST- 2016/05/06 06:00 [entrez]
AID - CVP-EPUB-75445 [pii]
AID - 10.2174/1570161114666160505143003 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2016;14(5):481-486. doi: 10.2174/1570161114666160505143003.